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INTRODUCTION
Among the critically ill, infectious diseases can play a significant role in the etiology of 
neuropsychiatric disturbances. All critical care physicians are familiar with delirium as a 
secondary complication of systemic infection. This article focuses on key infectious diseases 
that commonly and directly produce neuropsychiatric symptoms, including direct infection 
of the central nervous system (CNS), human immunodeficiency virus (HIV) infection, and 
AIDS.
HIV-AIDS is often seen as the modern “great imitator,” a complex infectious disease with 
multiple manifestations and interplay of myriad biopsychosocial factors, including 
neuropsychiatric disorders related to direct HIV-1 brain invasion, CNS opportunistic 
infections, manifestations of concurrent drug abuse, hepatitis C coinfection, and iatrogenic 
complications. Differential diagnosis and management of HIV-AIDS–related 
neuropsychiatric disturbances can serve as a paradigm for other infectious diseases that have 
neuropsychiatric manifestations.
MEDICAL HOSPITALIZATION IN HUMAN IMMUNODEFICIENCY VIRUS–AIDS
With the widespread availability of highly active antiretroviral therapy (HAART) for HIV 
infection in developed countries, there have been dramatic declines in HIV-related hospital 
admissions. Between 1995 and 1997, admissions dropped 33% to 75%.1–4 Since that time, 
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rates have stabilized or rebounded slightly. The reasons for medical hospital admission have 
also shifted. In 2 urban hospital studies,3, 4 a drop in hospitalization caused by opportunistic 
infections and cancers was observed, contrasting with a rise in nonopportunistic 
complications, such as hepatitis C and cardiovascular disease. Mean CD4 counts of HIV 
inpatients were seen to increase by more than 100 cells/mm3 from 1995 to 2001.3 During 
1990 to 2011, among persons with AIDS, the annual rate of death due to HIV-attributable 
causes has also decreased by 89%.5
Factors that seem to confer risk for medical hospitalization in the HAART era include low 
CD4 count, female gender, lack of antiretroviral treatment, and injection drug use.3, 4 The 
sociodemographic characteristics of those at risk reflect the shifting demographics of the 
HIV epidemic, limitations in access to care, and poor adherence to antiretroviral treatment.
EPIDEMIOLOGY OF PSYCHIATRIC DISORDERS IN MEDICAL INPATIENTS 
WITH HUMAN IMMUNODEFICIENCY VIRUS–AIDS
There are extensive epidemiologic data regarding psychiatric disorders in ambulatory 
patients with HIV-AIDS. Overall, studies reveal high rates of lifetime and current substance 
abuse and depressive and anxiety disorders (see Ferrando and Tiamson6 for a review of this 
literature). As seen in Table 1, among medially hospitalized patients with HIV, studies 
indicate a similar profile; however, delirium, dementia, and manic-spectrum disorders seem 
to be more common.7–11 The most frequently diagnosed disorders are in the depressive 
spectrum (range, 27%–83%), including depression secondary to medical condition (or 
organic mood disorder), adjustment disorder with depressed mood, major depressive 
disorder, or dysthymic disorder. Delirium is diagnosed in 8% to 29% of patients, regardless 
of HIV stage, and is often reported to be concurrent with HIV-associated dementia, 
diagnosed in 8% to 22% of cases. Substance use disorders are diagnosed in 11% to 36% of 
inpatients with AIDS and up to 63% in patients who are HIV-positive without AIDS. One 
study found that bipolar disorder and HIV-associated mania occurred in 11% of medical 
inpatients.11
HUMAN IMMUNODEFICIENCY VIRUS AND THE BRAIN
Since the beginning of the HIV epidemic, it has been recognized that HIV can infect the 
CNS and produce a range of cognitive and behavioral symptoms that become more frequent 
and severe as the immune system declines and symptomatic illness and AIDS ensue. In 
1991, the American Academy of Neurology published research diagnostic criteria for HIV-
associated cognitive, motor, and behavior disorders,12 which remained in widespread use 
until the diagnostic criteria were recently updated by a work group convened at the National 
Institute of Mental Health.13 Based on cumulative research and clinical evidence, this group 
described 3 HIV-associated neurocognitive disorders (HANDs): (1) asymptomatic 
neurocognitive impairment, (2) mild neurocognitive disorder, and (3) HIV-associated 
dementia. The asymptomatic neurocognitive impairment category recognizes that a 
substantial percentage of patients who infected with HIV have demonstrable impairment on 
neuropsychologic testing but little or no perceptible functional impairment. The latter 2 
disorders (mild neurocognitive disorder and HIV-associated dementia) present with 
Munjal et al. Page 2
Crit Care Clin. Author manuscript; available in PMC 2018 January 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cognitive and behavioral symptoms associated with functional impairment (mild in mild 
neurocognitive disorder, moderate to severe in HIV-associated dementia). HANDs have been 
found to predict shorter survival,14, 15 especially in the setting of virologic failure on 
HAART.16 The cognitive symptoms of HANDs are characteristic of subcortical-frontal 
pathology and include impairment in psychomotor processing speed, executive function, and 
verbal memory. The potential behavioral manifestations are broad and include apathy, 
depression, anxiety, mania, and psychosis.
Neuropathologically, HIV traverses the blood-brain barrier primarily by infected blood 
mononuclear cells, becoming activated macrophages once they enter the brain. Onset of 
neural injury may date to initial viral invasion and the transient early period of unchecked 
viremia and marked immunosuppression of the seroconversion period.17 Neuropathologic 
changes seem to be a result of CNS immune activation with release of neurotoxic cytokines 
and metabolites. Substance abuse is an important cofactor for HIV neuropathology.18 
Subcortical brain structures, such as the basal ganglia and periventricular white matter, are 
most affected. If unchecked, this immune cascade leads to neuronal cell apoptosis. Effective 
suppression of CNS viral replication and the resulting immune activation has the potential, 
however, to reverse at least some of the neuropathologic changes.
HIV-associated neuropathology has received heightened attention in recent years because of 
2 associated developments. First, HIV-1 viral load monitoring has demonstrated that the 
CNS is an independent sanctuary site of viral replication.19 The level and genetic profile of 
HIV in the peripheral circulation may not correlate with that in the CNS. The second 
development relates to the recognition that antiretroviral medications have differing levels of 
penetration into the CNS. It is hypothesized that poorly penetrating antiretrovirals might 
inadequately treat CNS infection despite being effective peripherally. This has led to 
concerns that actively replicating virus in the CNS could cause progressive cognitive decline 
in otherwise healthy HIV-positive individuals and could also lead to a reseeding of the virus 
into the peripheral circulation. Indeed, better CNS antiretroviral penetrance has been found 
to correlate with better suppression of HIV in the cerebrospinal fluid (CSF).20 However, this 
approach is controversial, as higher CSF Penetration Effectiveness scores correlate with 
lower HIV RNA load in the CSF but do not necessarily correlate with better cognition.21 
HAND is common in patients with HIV on combination treatment with a reported frequency 
of 25% to 47%.22 There has been a reduction in the incidence of HIV-associated dementia 
from 7% per year in the pre-HAART era to approximately 2% to 3%.23 However, cases still 
occur in patients with HIV who are untreated, inadequately treated, or in persons who have 
“CNS escape” (a phenomenon in which antiretroviral therapy [ART] controls HIV in the 
periphery but not in the CNS).24 HAART regimens have been shown to reduce CSF viral 
load to undetectable levels,19 to reverse white matter lesions on MRI,25 to reverse brain 
metabolic abnormalities detected by proton magnetic resonance spectroscopy,26 and also to 
improve neuropsychologic test performance.27–29 Despite these hopeful findings, however, 
functionally significant cognitive and behavioral disturbances, without frank dementia, may 
persist in approximately one-fourth of patients treated with HAART,30, 31 impeding 
adherence to treatment32 and ability to work.33
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DIFFERENTIAL DIAGNOSIS
Differential diagnosis is paramount when investigating for medical and neuropsychiatric 
etiologic factors related to HIV illness and its treatment (Box 1).
First, in assessing the hospitalized patient with HIV-AIDS, it is important to query for 
personal and family psychiatric history because neuropsychiatric complications may be a 
manifestation of preexisting psychopathology.34, 35 Even in the presence of a prior 
psychiatric history, however, it is imperative to rule out potentially exacerbating, if not 
etiologic, medical factors. HANDs are associated with a range of cognitive or behavioral 
symptoms, including apathy, depression, sleep disturbances, mania, and psychosis. CNS 
opportunistic illnesses and cancers also can present with a wide range of neuropsychiatric 
symptoms as a result of both focal and generalized neuropathologic processes (Table 2).
Substance intoxication and withdrawal also are common in the medical inpatient setting. 
HIV-infected substance users have high rates of preexisting comorbid psychopathology that 
may be exacerbated by ongoing substance use. Further, abuse of multiple substances 
concurrently (eg, opioids, cocaine, benzodiazepines, alcohol) can result in complex 
intoxication and withdrawal states that may be very difficult to treat.
Hepatitis C coinfection is associated with multiple neuropsychiatric complaints, most 
frequently fatigue, depression, and cognitive dysfunction. The pattern of cognitive 
impairment is similar to that of HIV, with impairment in attention, concentration, 
psychomotor processing speed, verbal memory, and executive dysfunction. Patients with 
end-stage liver disease and cirrhosis experience superimposed delirium (hepatic 
encephalopathy). Combination pegylated interferon alpha-2a treatment for hepatitis C has 
been extensively documented to cause neuropsychiatric side effects, including depression, 
suicidal ideation, anxiety, sleep disturbance, fatigue, mania, psychosis, delirium, and 
cognitive dysfunction.36
Multiple antiretroviral and other medications used in the context of HIV have been reported 
to have neuropsychiatric side effects. These include zidovudine, didanosine, abacavir, 
nevirapine, efavirenz, and interferon alpha-2a.37 Most of these are uncommon or rare and 
causal relationships are often difficult to determine. The most widespread clinical concern 
has been generated by reports of sudden-onset depression and suicidal ideation associated 
with interferon alpha-2a and efavirenz. Early reports suggested that efavirenz may be 
associated with at least transient neuropsychiatric side effects in excess of 50% of patients.38 
Reported effects are protean and include depression, suicidal ideation, vivid nightmares, 
anxiety, insomnia, psychosis, cognitive dysfunction, and antisocial behavior. Drug 
interactions between antiretroviral and psychotropic medications are important aspects of 
differential diagnosis in the hospital setting. In one study, HIV-AIDS medical inpatients 
were prescribed an average of 7 medications during their admission.11 Factors influencing 
drug-drug interactions include medical illness severity, prior substance abuse, the likelihood 
of multiple medications being initiated simultaneously, changes in volume of distribution 
and protein binding, and hepatic and renal impairment.
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Inpatients with HIV-AIDS often experience endocrinologic derangements that may produce 
behavioral symptoms. These include clinical and subclinical hypothyroidism, 39 
hypogonadism,40 adrenal insufficiency,41 and Graves disease (autoimmune thyroiditis).39 
Thyroid deficiency, including its subclinical forms, is present in approximately 36% of HIV- 
infected patients.39 Testosterone deficiency, with clinical symptoms of hypogonadism, is 
present in up to 50% of men with symptomatic HIV or AIDS and is likely to be present with 
concurrent acute medical illness.40 Deficiency of adrenal glucocorticoid production is 
present in up to 50% of severely ill patients with HIV.41 These endocrine deficiency states 
have been associated with fatigue, low mood, low libido, and loss of lean body mass and 
may be ameliorated by correction of the deficiency. Graves disease presents in the acute 
stages with activation symptoms including anxiety, irritability, insomnia, weight loss, mania, 
and agitation.
DIAGNOSTIC EVALUATION
The psychiatric evaluation of the inpatient with HIV-AIDS is consistent with the broad 
differential diagnosis and is focused on identifying potentially reversible underlying 
etiologies. A thorough psychiatric evaluation, including presenting symptoms, personal and 
family history of psychiatric illness and substance abuse, and a cognitive functioning 
examination are essential. Box 2 contains a listing of such diagnostic tests.
In general, the diagnostic workup should include complete blood count with differential, 
serum chemistries (including liver and renal function tests, fasting glucose, and creatine 
phosphokinase), chest radiograph, electrocardiogram, blood and urine cultures (if indicated), 
toxicology screen, and psychotropic medication serum levels (when available). Depending 
on the clinical presentation, assays of thyroid function; vitamins B6 and B12; Venereal 
Disease Research Laboratory; serum total, free, or bioavailable testosterone; 
adrenocorticotropic hormone stimulation; and 24-hour urinary cortisol may be obtained. If 
brain imaging is required, MRI of the brain with gadolinium contrast is preferred over 
computed tomography (CT) because it produces better visualization of brain tissue and of 
subcortical and posterior fossa structures and focal lesions. A lumbar puncture also may be 
obtained if necessary under sedation with fluoroscopic guidance. Results are often 
nonspecific, but important studies include opening pressure; culture (viral, fungal, 
mycobacterial); cell count; protein; neopterin; b2-microglobulin; and polymerase chain 
reaction testing for cytomegalovirus, Epstein-Barr virus, John Cunningham (JC) virus, 
herpes simplex virus (HSV), and HIV-1.
PSYCHIATRIC DISORDERS IN HUMAN IMMUNODEFICIENCY VIRUS–AIDS 
AND THEIR TREATMENT
Depression
Depression is the most common psychiatric symptom and diagnosis among medical 
inpatients with HIV-AIDS. Symptoms are often attributed to adjustment disorder or to 
medically related (organic) factors that may be transient, related to improvement in physical 
symptoms. Major depressive disorder (MDD) may be a reaction to an HIV diagnosis, 
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medical illness, HIV stigma, or the direct CNS effects of HIV as mediated by altered 
cytokine and neurotransmitter metabolism.42 Identifying and treating MDD is important to 
long-term management because prolonged MDD is associated with decreased adherence to 
ART.43, 44 In one prospective study assessing depressive symptoms at admission and 
discharge, however, 28% of medical inpatients with HIVAIDS had severe depression that 
persisted at discharge.45 In another study, 76% of patients who had a depressive disorder 
during their admission continued to have significant depressive symptoms 3 to 6 weeks after 
discharge, with significant predictors of depression during and after medical hospitalization 
including being a woman, having an AIDS diagnosis, and having poor social support.11
In the medical inpatient setting in particular, the diagnosis of depressive disorder in HIV-
infected patients may be confounded by somatic symptoms common to depression, HIV 
illness, and its complications. HIV infection stimulates rising levels of proinflammatory 
cytokines, such as interleukin-6, interleukin-1 beta, tumor necrosis factor-alpha and 
interferon-gamma, that are associated with “sickness behavior” (fever, hypersomnia, 
anorexia, decreased motor activity, and loss of interest in the environment).46 These include 
fatigue, appetite loss, sleep disturbance, and cognitive disturbances. Generally, in the 
presence of persistent depressed mood or loss of interest, an inclusive approach toward 
somatic symptoms is preferred. This is because affective and somatic subscales of 
depression screening instruments (eg, the Beck Depression Inventory) are highly 
intercorrelated, that these symptoms are more closely linked to measures of depression than 
to measures of HIV disease severity, and that both affective and somatic symptoms improve 
with antidepressant treatment.47, 48 However, persons with HIV may be screened using the 
Beck Depression Inventory for Primary Care, a tool that focuses on nonphysical symptoms 
as well.49
In the medical inpatient setting, when antidepressant medication treatment is considered, 
particular attention must be paid to side-effect profile, hepatic and renal function, and the 
potential for drug interactions. In addition to standard antidepressants, such as serotonin and 
serotonin-norepinephrine reuptake inhibitors, the initiation of psychostimulants and anabolic 
steroids, particularly testosterone, is frequently used in the inpatient setting and is given 
particular attention here.
Psychostimulants have been studied for the treatment of depressed mood, fatigue, and 
cognitive impairment in the context of HIV infection, particularly in advanced illness and 
where rapid onset of action is desirable. Agents studied include methylphenidate (5–90 
mg/d), dextroamphetamine (5–20 mg/d), pemoline (35–150 mg/d), and the wakefulness 
agent modafinil (50–200 mg/d).50–53 These agents are efficacious in treating depressive 
symptoms in patients with advanced HIV. The primary side effect is overstimulation.
Testosterone deficiency, with clinical symptoms of hypogonadism (depressed mood, fatigue, 
diminished libido, decreased appetite, and loss of lean body mass) is present in up to 50% of 
men and women with symptomatic HIV or AIDS.40 The most common screening test for 
testosterone deficiency is total serum testosterone (deficiency is defined as <300–400 ng/dL 
in men); however, serum-free (deficiency: <5–7 pg/mL in men; <3 pg/mL in women) and 
bioavailable testosterone may be more accurate measures. For testosterone replacement in 
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men, commonly used testosterone preparations include esterified depot testosterone 
(propionate, enanthate, cypionate, initiated at 100–200 mg intramuscularly every 2 weeks, 
maximum 400 mg intramuscularly weekly), transdermal skin patches (1 to 2 patches, 5–10 
mg, to clean, dry skin daily), and transdermal testosterone gel (1 to 4 packets, 25–100 mg, to 
clean, dry skin daily), with the depot preparations being the least expensive and most 
studied. Patch and gel formulations may produce less variability in serum testosterone levels 
and in target symptoms. In women, transdermal testosterone, 150 mg per day or equivalent, 
may be used to improve energy, well-being, muscle mass, and restore normal menstrual 
functioning.40 Reported side effects for men include irritability, tension, reduced energy, hair 
loss, testicular atrophy, reduced ejaculate volume, and acne. For women, there is particular 
concern for virilizing side effects; however, clinically these have been minimal in the setting 
of physiologic replacement dosing in the range described.
Delirium
The most common neuropsychiatric complication in hospitalized patients with AIDS is 
delirium.54 Delirium is diagnosed in 11% to 29% of hospitalized patients with HIV-AIDS. 11 
There are no data regarding specific or distinguishing symptom characteristics for the 
delirium seen in patients with HIV. Both the hypoactive and hyperactive variants of delirium 
are seen, and in addition to cognitive disturbance, symptom manifestations include apathy, 
dysphoria, agitation, fearfulness, delusions, and hallucinations.55
Delirium in the patient with HIV-AIDS is often superimposed on HANDs, particularly 
dementia, and patients with these disorders are at increased risk for the development of 
delirium when medically hospitalized. The etiology of delirium in patients with HIVAIDS is 
generally multifactorial. Breitbart and colleagues55 reported a mean of 12.6 medical 
complications in 30 delirious patients with AIDS, with the most common being hematologic 
(anemia, leukopenia, thrombocytopenia, hypoalbuminemia) and infectious diseases (eg, 
septicemia, systemic fungal infections, Pneumocystis carinii pneumonia, tuberculosis, and 
disseminated viral infections). Other potential etiologies were discussed previously in the 
differential diagnosis section.
Central to the treatment of delirium is treatment of its underlying medical causes. 
Symptomatic treatment includes educational, environmental, and psychopharmacologic 
interventions. Education regarding the risk and nature of delirium delivered to patients, their 
families, and the treatment team can be preventive and can result in earlier treatment and 
improved outcomes. Environmental interventions include titrating the level of stimulation, 
sitting the patient up, placing patients next to a window, frequent orientation, stabilizing 
sleep-wake cycles, and placing familiar people and orienting objects in the room.
In terms of pharmacologic treatment, most practitioners treat delirium with atypical 
antipsychotics, including olanzapine (available with dissolving oral preparation and 
intramuscularly), risperidone (available in dissolving oral preparation), quetiapine, 
aripiprazole (available intramuscularly), and ziprasidone (available intramuscularly). The 
only double-blind clinical trial of delirium treatment in AIDS, however, compared 
haloperidol, chlorpromazine, and lorazepam.55 In that study, Breitbart and colleagues55 
screened medical inpatients with HIV for delirium. Treatment was initiated early, and when 
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symptoms were mild to moderate in degree. Patients were severely medically ill, because 9 
(30%) of the 30 patients died within 1 week after completing the protocol. There were 3 
important findings. First, haloperidol (mean dose, 2.8 mg/d acutely and 1.4 mg/d 
maintenance) and chlorpromazine (mean dose, 50 mg/d acutely and 36 mg/d maintenance) 
were equally efficacious. Second, the lorazepam arm (mean dose, 3 mg acutely) was stopped 
early because of worsening of delirium symptoms, including oversedation, disinhibition, 
ataxia, and increased confusion. Third, adverse effects in the antipsychotic arms were 
limited and included mild extrapyramidal symptoms (EPS), such as decreased 
expressiveness, rigidity, tremor, and mild akathisia. Open-label studies and case reports 
suggest that the atypical antipsychotics clozapine, risperidone, and ziprasidone benefit 
patients with AIDS with psychosis and/or delirium.56
Delirium is common in hospitalized patients with HIV-AIDS, who should be assessed 
frequently for early detection and treatment. A combination of psychoeducational, 
environmental, and pharmacologic interventions, primarily with neuroleptic medications, is 
recommended. Benzodiazepines should be avoided, except in cases of severe agitation that 
fails to respond to antipsychotic agents or patients experiencing delirium secondary to 
alcohol or other CNS-depressant agent withdrawal, and patients should be monitored closely 
for the emergence of EPS. There is a higher susceptibility of patients with HIV to EPS, even 
with exposure to drugs with low potential for inducing EPS.57 Extreme sensitivity to EPS is 
encountered in patients with HIV-dementia.58 Marked neuronal degeneration in the basal 
ganglia of patients with HIV may contribute to these findings because of the accompanying 
dopaminergic neuron destruction and/or alteration.59
Mania
Manic symptomatology has been reported in 11% of all medically hospitalized patients with 
HIV-AIDS11 and may be seen in conjunction with primary bipolar illness or with CNS HIV 
infection (HIV-associated mania). Descriptively, HIV-associated mania is found to be a late-
onset, secondary affective illness associated with HIV infection of the brain, being less 
associated with a personal or family history of mood disorder. In addition, the 
symptomatology of HIV-associated mania may include more irritability, less 
hypertalkativeness, and more psychomotor slowing and cognitive impairment compared 
with primary bipolar mania.60 Given that HIV-associated mania is directly related to HIV 
brain infection, antiretroviral agents that penetrate the blood-brain barrier may offer some 
protection from incident mania.61 The mechanisms are poorly understood; however, the HIV 
nef protein is reported to alter CNS dopamine metabolism leading to hyperactive, 
“maniclike” behaviors in animal models.62
The choice of psychotropic drugs to treat HIV mania is based on case reports, and open-
label studies, rather than randomized controlled trials, as well as the desire to avoid adverse 
drug interactions, and the avoidance of HIV-specific side effects. HIV mania may improve 
with an approach that combines resolution of the underlying CNS process, use of a mood-
stabilizing drug, and/or addition of an antipsychotic drug.63 Valproic acid is metabolized in 
the liver, and liver disease is common in HIV-positive persons; further, valproic acid has 
interactions with many ART drugs.64, 65 This must be weighed against the potential 
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disadvantages of other mood stabilizers, such as lithium, which can exacerbate renal disease, 
or carbamazepine, which can induce bone marrow suppression, hepatotoxicity, and induce 
the metabolism of ART (particularly protease inhibitors).64, 66 Lamotrigine has been tested 
for HIV-associated peripheral neuropathy and may be useful for treating mixed mania or 
bipolar depression in HIV; however, patients with overt manic symptomatology generally 
require a traditional mood stabilizer. This anticonvulsant requires careful upward dose 
titration because of risk of severe hypersensitivity (Stevens-Johnson syndrome).
Given the limitations of mood stabilizers in HIV, there is widespread clinical use of atypical 
antipsychotics for acute and maintenance treatment of HIV-associated mania; however, there 
are no clinical trial data. Clinicians generally choose olanzapine, risperidone, ziprasidone, or 
quetiapine as alternatives to traditional mood stabilizers58, 67; however, these agents may 
exacerbate metabolic syndrome or cause EPS in patients with extensive basal ganglia HIV 
involvement. Benzodiazepines may be useful for adjunctive treatment, but acute and 
maintenance therapy may be complicated by tolerance, dependence, and cognitive 
impairment, including the possibility of causing delirium and disinhibition.
Psychosis
HIV infection may be directly linked to the onset of psychosis, which is defined by the 
presence of thought disorder, hallucinations, or delusions. Psychosis in HIV is most often a 
manifestation of substance intoxication or withdrawal, delirium, HANDs, mood disorders 
with psychotic features, or schizophrenia. Estimates of the prevalence of new-onset 
psychosis in patients with HIV range from 0.5% to 15.0%.68 One study compared 20 HIV-
infected patients with new-onset psychosis (and no prior psychotic episodes or current 
substance abuse) with 20 nonpsychotic patients matched for demographics and HIV illness. 
The former group tended to have worse global neuropsychologic impairment, was more 
likely to have a prior history of substance abuse, and had significantly higher mortality at 
follow-up, suggesting that psychotic patients with HIV-AIDS had an increased CNS 
vulnerability.69
Persons with HIV-associated secondary psychosis are reported to show more disorders of 
consciousness, orientation, attention, and memory than patients with primary serious mental 
illness.70 They also tend to report less bizarre delusions, have a more variable course, and 
are more likely to have eventual remission of their psychosis.71
Patients infected with HIV with primary psychotic disorders, such as schizophrenia and 
schizoaffective disorder, may have poor access to HIV care, may present to the emergency 
and medical inpatient setting with untreated advanced HIV illness, and may be at risk for 
poor adherence to care, unless provided with comprehensive supportive services, including 
psychiatric treatment, housing, and community case management.
In general, treatment with antipsychotic medication requires awareness of HIV-infected 
patients’ susceptibility to neuroleptic-induced EPS as a result of HIV-induced neuronal 
damage to the basal ganglia. Movement disorders (acute dystonia, parkinsonism, ataxia) can 
be seen in advanced HIV disease in the absence of antipsychotic exposure. General 
recommendations include avoidance of high-potency D2 blocking agents (eg, haloperidol), 
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avoidance of depot neuroleptics, and the consideration that maintenance antipsychotic 
medication may not be necessary for the complete remission of new-onset or transient 
psychotic symptoms. Most clinicians prefer the use of atypical antipsychotics in this 
population; however, they are associated with development of metabolic syndrome, cardiac 
problems, and obesity.72
A literature search on the use of antipsychotic medication in HIV-AIDS revealed 6 studies 
published since 1993; these studies described treatment of psychosis occurring in delirious, 
schizophrenic, and manic patients. Agents reported in the literature include haloperidol 
(mean dose, 3 mg),73 clozapine (mean dose, 27 mg/d),74 risperidone (mean dose, 3.3 mg/
d),75 and olanzapine (10–15 mg/d).76 Haloperidol was reported to have a high incidence of 
EPS and caution is encouraged with clozapine because of the risk for agranulocytosis and 
interaction with ritonavir.
Anxiety
Anxiety is common in patients who are HIV-positive, estimated to occur in 22% to 47%. 
Generalized anxiety disorder has been found to range between 6.5% and 20.0% in HIV 
samples.77, 78 Posttraumatic stress disorder is a common anxiety disorder in persons with 
HIV, estimated at 10% to 54% among populations such as men who have sex with men, 
minority women, and those with persistent pain.79, 80 Patients who are HIV positive with 
subclinical or overt neurocognitive impairment are more sensitive to the side effects of 
anxiolytic medications and should start at low doses. Drug-drug interactions have been 
reported with anxiolytics and AIDS medications; for example, there are case reports of 
patients who are HIV-positive on protease inhibitors who experienced prolonged sedation 
when given midazolam.81 Buspirone, a popular antianxiety agent and 5HT1A agonist, has 
been reported to cause extrapyramidal signs when given with protease inhibitors such as 
ritonavir.82 Anxiety also interferes with ART adherence.83
Members of the Organization of AIDS Psychiatry participated in a Web-based survey. 
Consensus emerged regarding first-line treatment for depression (escitalopram/ citalopram), 
for psychosis and secondary mania (quetiapine), and for anxiety (clonazepam).84
Herpes Simplex Encephalitis
Several viruses can cause viral encephalitis including HSV.85 HSV is the etiologic agent for 
herpes simplex encephalitis (HSE), the most common source of acute viral encephalitis in 
the United States, with an annual incidence of 2000 cases yearly.85, 86 Two principal forms 
of HSV exist: HSV-1, which typically leads to orolabial lesions; and HSV-2, which is 
responsible for genital herpes lesions. HSV-2 infections more typically result in aseptic 
meningitis, whereas HSV-1 causes HSE. HSE is a potentially lethal infection with a 
mortality rate of up to 70% if left untreated and 14% to 20% with treatment. 85, 87 Half of 
HSE cases occur in people older than 50, whereas a third of cases are in people younger than 
20.88
Clinically, HSE often presents with acute onset of symptoms, such as fever, altered mental 
status, seizures, and focal neurologic signs, such as aphasia and hemiparesis. Without 
treatment, patients may progress to coma.86 Before the acute presentation, there may be a 
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prodrome characterized by headache, fatigue, mild fever, and irritability. It is hypothesized 
that HSV-1 enters the brain via the olfactory nerves and spreads into the limbic system, 
frontal, and temporal lobes. Infected neurons and other cells can undergo cytolysis, causing 
hemorrhagic destruction of brain tissue. Particularly vulnerable areas include the fronto-
orbital region, temporal lobes, hippocampus, cingulate gyrus, and insular cortex.89
HSE leaves up to 80% of people who survive infection with a number of residual cognitive 
and neuropsychiatric sequelae.85 Cognitively, patients may experience significant limitations 
in anterograde memory formation with additional impairment in retrograde memory. The 
cognitive effects of HSE are dependent on the sites of the brain involved. Although HSV-1 
infection is often bilateral, impairments seen clinically may be dependent on lateralization of 
HSV-1–related brain injuries. In particular, right hemispheric involvement often leads to 
subtle deficits with less functional impairment. Left hemispheric neuronal damage, however, 
creates difficulties in language function and verbal memory.85 Additional impairments, such 
as semantic aphasia or mutism, are found in up to 46% of patients with HSE and, more 
rarely, auditory agnosia also has been documented.85, 86 Long-term consequences of HSE 
include memory impairment and behavioral and personality changes.85 
Neuropsychiatrically, patients may exhibit symptoms of aggression and disinhibition 
consistent with a Klüver-Bucy syndrome. Early treatment may ameliorate some of these 
symptoms; however, particularly in the young and old, cognitive impairments secondary to 
HSE may lead to postencephalitic dementia.85, 90
HSE is diagnosed by using a combination of clinical features and laboratory and imaging 
findings (Table 3). Noncontrast CT imaging demonstrates abnormalities in up to 50% of 
scans, including a midline shift. MRI, however, remains the most sensitive imaging tool in 
diagnosing HSE and is recommended as the first diagnostic step after the clinical 
examination.86 MRI findings include focal hyperintensities on T2-weighted imaging. 
Electroencephalography (EEG) also may be used and initially may show some generalized 
or focal slowing over the temporal lobes (sites that are commonly a focus for HSV-1 
infection), but may change to lateralized, epileptiform activity.85 Lumbar puncture may 
demonstrate an elevated opening pressure, CSF leukocytosis, and xanthochromia in addition 
to a normal CSF glucose level. Polymerase chain reaction demonstrates the presence of 
HSV-1 infection in the CSF.
HSE is treated with intravenous acyclovir (60 mg/kg per day, given in 3 divided doses) for 
21 days.91 A repeat CSF examination should be performed at the end of therapy to ensure 
that the virus has cleared. The use of continued outpatient treatment with oral valacyclovir is 
common but has not been shown to improve outcomes.92 Recovery is determined in part by 
how quickly treatment is begun, with increased morbidity and mortality associated with 
delays in treatment.88 Although acyclovir treatment of HSV infection in HSE is widely 
accepted, there is no well-defined treatment specific for the cognitive and neuropsychiatric 
symptoms associated with HSE. It has been proposed that using dopamine antagonists in a 
carefully monitored manner may be useful in treating the behavioral disturbances associated 
with HSE in the acute period. This is based on evidence from an animal study suggesting 
activation of the mesostriatal dopamine system in HSE. Other treatments used in clinical 
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practice for the neurobehavioral sequelae of HSE include anticonvulsants, benzodiazepines, 
antipsychotics, stimulants, mood stabilizers, and cholinesterase inhibitors.85, 93
PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED 
WITH STREPTOCOCCAL INFECTIONS
Over the past 25 years, there has been mounting evidence for connections between group A 
b-hemolytic streptococcal (GAS) infections and the development of neuropsychiatric 
symptoms. Sir William Osler made the original observation that patients with Sydenham 
chorea, a complication of GAS infection, also exhibited behaviors consistent with tics and 
obsessive-compulsive disorder (OCD). Later work demonstrated that as many as 70% to 
80% of patients with Sydenham chorea also have clinical features meeting diagnostic criteria 
for OCD, particularly in children.94, 95 Based on work with children who exhibited abrupt 
onset of OCD symptoms or tics following GAS infection, the development of these 
symptoms was linked to an immune system–mediated response to the original infection, 
termed “pediatric autoimmune neuropsychiatric disorders associated with streptococcal 
infections” (PANDAS).94, 96 Age of symptom onset is approximately 3 years younger in 
PANDAS than childhood-onset OCD. Additionally, the abrupt onset and relapsing-remitting 
pattern of symptoms in PANDAS differs from the more gradual onset and chronic pattern in 
childhood OCD.95, 97 There may be a heritable component to PANDAS, because children 
with PANDAS have parents and grandparents with significantly higher rates of streptococcal 
infection complications, such as rheumatic fever, compared with controls.96
Diagnostic criteria for PANDAS include (1) age of onset between the ages of 3 and 11 years; 
(2) meeting criteria for OCD or a tic disorder; (3) episodic severity of symptoms; (4) 
association with GAS infection; and (5) association with neurologic abnormalities, including 
hyperactivity, tic, or choreoform movements.94, 95 Although resembling childhood-onset 
OCD, PANDAS is distinguished clinically by a distinct temporal relationship between a 
GAS infection and onset of OCD or tics.
Experts convened at the National Institutes of Health in July 2010, given the agreement that 
a subgroup of children with OCD have an abrupt onset of symptoms accompanied by a 
variety of severe and acute neuropsychiatric symptoms. Given the ongoing controversy 
about the etiology of the symptoms, experts proposed an expanded clinical syndrome, 
pediatric acute-onset neuropsychiatric syndrome (PANS) or childhood acute 
neuropsychiatric symptoms (CANS), which may be caused by noninfectious (eg, drugs, 
metabolic abnormalities) or infectious (eg, group A streptococci) triggers. Proposed 
diagnostic criteria for PANS/CANS include the following:
• Abrupt, dramatic onset of OCD or severely restricted food intake
• At least 2 concurrent severe neuropsychiatric symptoms (eg, anxiety, depression, 
emotional lability), also with acute onset
• Symptoms not better explained by a known neurologic or medical disorder (for 
example, Sydenham chorea, systemic lupus erythematosus, Tourette 
disorder)98, 99
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To make a more definitive diagnosis (see Table 3), obtaining antistreptococcal antibody titers 
(including antistreptolysin O [ASO] and antideoxyribonuclease B [ADB] antibodies) that 
rise during a symptomatic exacerbation and fall with symptomatic improvement is often 
needed. Serologic diagnosis of recent GAS infection can be made by demonstrating a 0.2 
log10 rise (a 58% increase) in either ASO or ADB, ordinarily obtained 4 to 8 weeks apart, 
although only 62% of new GAS acquisitions were followed by such a rise. A single high 
titer, rather than serial acute and convalescent titers, is not diagnostically reliable, but may be 
considered contributory if levels exceed twofold (0.3 log10) above the laboratory’s stated 
upper limit of normal, because these higher levels are uncommon in children without recent 
streptococcal infection.100 Use of these antistreptococcal antibody titers, however, is 
complicated because titers may remain high for months after infection.95 There is also 
evidence that antibodies directed against the basal ganglia are found more commonly in 
patients with PANDAS relative to people with uncomplicated streptococcal infections.101 
This finding may shed further light on the pathophysiology of PANDAS, given that 
preliminary MRI suggests basal ganglia enlargement in patients with PANDAS.102 In 
determining susceptibility to PANDAS, studies have indicated that patients with PANDAS 
are more likely to also have lymphocytes that are positive for the D8/17 marker. This B-
lymphocyte alloantigen marker is also associated with other streptococcal-related conditions, 
such as rheumatic fever and Sydenham chorea, further suggesting an immune basis.94, 95
Ultimately, based on the clinical and diagnostic features of PANDAS, it has been suggested 
that the pathophysiology of PANDAS is based on the development of an autoimmune 
reaction in patients who are susceptible (ie, based on family history, immunologic markers). 
This reaction occurs in response to infection with GAS in which the immune system 
inappropriately generates antibodies against epitopes on the basal ganglia that resemble 
streptococcal antigens through the process of molecular mimicry.95 The resulting immune-
mediated inflammatory process in the basal ganglia then may lead to the clinical features of 
PANDAS.96
Most instances of PANS are suspected to be postinfectious in origin, although no single 
microbe other than GAS has yet been consistently associated with the onset of PANS. 
Therefore, a detailed review and documentation of associated febrile and nonfebrile 
infectious illnesses, including signs and symptoms and diagnostic testing, is advised. The 
most commonly observed antecedent infection seems to be upper respiratory infection, 
including rhinosinusitis, pharyngitis, or bronchitis. It is not yet clear if any 1 of those 3 
presentations is more likely than the others to be associated with the initiation of PANS. 
Mycoplasma pneumoniae, influenza, Epstein-Barr virus, and Lyme disease have been 
implicated to PANS onset or flares.103
Treatment of PANDAS has been largely based on immunomodulatory therapies. Notably, 
significant symptomatic improvements have been demonstrated in patients following use of 
plasma exchange and intravenous immunoglobulin (IVIG). In one study, severity of OCD 
symptoms diminished by 45% to 58% following treatment with either plasma exchange or 
IVIG.96, 104 Despite this, immunomodulatory therapies have not been recommended as the 
routine treatment of PANDAS.95 IVIG and plasma exchange both carry a substantial risk of 
adverse effects, and use of these modalities should be reserved for children with particularly 
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severe symptoms and a clear-cut PANDAS presentation.105 The US National Institutes of 
Health and American Academy of Neurology 2011 guidelines state there are inadequate data 
to determine the efficacy of plasmapheresis in the treatment of acute OCD and tic symptoms 
in the setting of PANDAS and insufficient evidence to support or refute the use of 
plasmapheresis in the treatment of acute OCD and tic symptoms in the setting of 
PANDAS.106 Use of antibiotic prophylaxis to prevent neuropsychiatric exacerbations 
following recurrent streptococcal infections has yielded mixed results. Although one double-
blind, placebo- controlled trial found no benefit over placebo in preventing PANDAS 
exacerbations, another trial found that either penicillin or azithromycin were able not only to 
lower rates of streptococcal infections but also to decrease symptom exacerbations in 
patients with PANDAS.107, 108 Evidence is insufficient to determine if tonsillectomy is 
effective.109
Children with OCD and/or tic disorders should receive standard neuropsychiatric treatment 
for these disorders (whether or not the children have evidence of recent GAS 
infection).110, 111 Treatment of neuropsychiatric symptoms should not be delayed pending 
confirmation of PANDAS (eg, documenting rise in antistreptococcal antibodies or while 
monitoring for a second episode).
The neuropsychiatric manifestations of children in the PANDAS subgroup respond to 
treatment with standard pharmacologic and behavior therapies.110 OCD symptoms generally 
respond to a combination of pharmacotherapy (typically a selective serotonin reuptake 
inhibitor) and cognitive behavior therapy. Motor and vocal tics can be treated with a variety 
of medications.
NEUROCYSTICERCOSIS
Neurocysticercosis (NCC) is the most common parasitic disease of the nervous system, 
particularly in developing countries in Asia, Latin America, and Africa. Because of rising 
rates of immigration from areas in which it is more prevalent, however, NCC is appearing 
more frequently in North America and Europe. Annually, more than 50,000 deaths 
worldwide are attributable to NCC. Even more patients are left alive with chronic, 
irreversible brain damage. Moreover, NCC is the major etiology for acquired epilepsy in 
endemic areas.112 NCC is caused by infection with the tapeworm Taenia solium. Humans 
are the definitive host for T solium, whereas pigs serve as the intermediate host. NCC results 
generally from fecal-oral transmission in which people ingest the eggs of the tapeworm from 
contaminated food or water. Commonly, this route of transmission occurs through handling 
of food by others already infected or from improperly cleaned food. Autoinfection also 
occurs, albeit less frequently.95 Once in the intestine, the eggs hatch and migrate throughout 
the body by way of the bloodstream, ultimately depositing into various tissues where they 
develop into the larval cysticercus form. When the site of larval deposition is in the CNS, 
NCC develops. Symptoms of NCC are dependent on the area and extent of nervous system 
involvement. The 4 main types of NCC are (1) parenchymal, (2) subarachnoid, (3) 
ventricular, and (4) spinal.95
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Neurologically, seizures are the most common manifestation of NCC, occurring in 80% of 
infected patients, especially in the parenchymal form of the disease.113 The seizures are 
typically simple partial or generalized tonic-clonic, although patients also may present with 
focal neurologic deficits based on the sites of infection. Stroke, intracranial hypertension, 
hydrocephalus, meningeal inflammation, fibrosis, or cyst formation also may occur.112 As a 
result, NCC is on the differential diagnosis of most neurologic disorders in endemic 
regions.114
Given the varied neurologic presentations of NCC, it is not surprising that NCC also has 
many different psychiatric manifestations. Up to 15% of people infected with NCC exhibit 
only psychiatric sequelae.115 In a study examining rates of T solium infection among 
chronic psychiatric inpatients in a community in Venezuela, 18.5% of the inpatients were 
infected versus 1.6% of controls.116 Commonly, patients present with acute psychiatric 
decompensation,95 mimicking psychotic states, such as schizophrenia. In one case report, 
NCC was marked by acute psychosis characterized by agitation, thought disorganization, 
paranoia, and auditory-visual hallucinations.112, 117 Other psychiatric manifestations of 
NCC include depression or dementia; suspicion for NCC-related dementia ought to be high 
if it occurs in patients who are younger, also have a history of seizures, have acute onset of 
symptoms, and are from an area in which NCC is endemic.95 In a recent study from Brazil, 
more than 80% of the patients with NCC reported depressive symptoms.118
The diagnosis of NCC is often difficult because the symptoms often resemble those from a 
broad differential of other disorders (see Table 3). NCC most commonly is diagnosed, 
however, from clinical history, imaging, and laboratory techniques. Besides biopsies that 
often prove difficult to do, brain imaging using CT and MRI scans allows for visualization 
of lesions from Taenia infection. In active disease, ring-enhancing lesions are most typically 
seen; visualization of the parasite’s scolex within a cystic structure is pathognomonic for 
NCC.112 Infection outside the brain parenchyma makes visualization more difficult.95 
Laboratory studies are often used to confirm the diagnosis by investigating patient serology 
for antibodies related to Taenia infection. Enzyme-linked immunosorbent assay and enzyme-
linked immunoelectrotransfer are often used for antibody detection.95 However, a weakness 
of the test is that it may be false negative in approximately 50% of patients with a single 
cerebral cyst or in those with calcifications alone. Another weakness is that it may be false 
positive in persons who had been exposed to the adult parasite without developing the 
disease.119
NCC treatment has been controversial, with few rigorous, large-scale studies conducted 
examining the various treatment options. The location of cysts; degree, size, and severity of 
local inflammation around lesions; and symptom severity all affect the treatment choice. 
This is complicated by findings that the treatments themselves may exacerbate the already 
present inflammatory response leading to symptomatic worsening.120 Nevertheless, NCC 
has been treated for more than 20 years using anti-helminthic agents, such as praziquantel 
and albendazole.95, 112, 120 Other agents may be given in concert with these drugs, including 
steroids (to treat pericystic inflammation and NCC-related encephalitis) and anticonvulsants 
(because of NCC-related seizures). The American Academy of Neurology issued a guideline 
document and concluded that albendazole plus corticosteroids should be considered for 
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patients with neurocysticercosis, as the use of these drugs reduces the number of viable cysts 
on control neuroimaging studies (level B of evidence) and the long-term risk of seizure 
recurrence (level B evidence).121 In some instances, surgery also may be needed for 
placement of ventricular shunts to treat hydrocephalus secondary to arachnoiditis.112, 120
NEUROSYPHILIS
Cases of syphilis have been documented since the late 1400s and, with the HIV epidemic in 
recent years, have had global resurgence. By the 1920s, more than 20% of patients in 
American mental hospitals had tertiary neurosyphilis (NS).122 With the advent of antibiotics, 
such as penicillin, the incidence and prevalence of syphilis and resultant NS dropped 
significantly; however, in parallel with the HIV epidemic, rates of infection (largely by 
sexual intercourse) began to rise again. There has been an 81% increase in cases of syphilis 
infection among men since 2000, with an annual incidence of 0.2 to 2.1 cases per 100,000 
immunocompetent individuals. 122–124 This has been an important health problem because 
syphilis facilitates coinfection with HIV.124 HIV causes impaired cell-mediated immunity, 
which accelerates the progression of syphilis, so that patients with HIV have a greater 
frequency of neurosyphilis.125
Known as the original “great imitator,” syphilis has a number of presentations in virtually all 
organ systems, including the CNS. Consequently, NS has been linked with a diverse array of 
cognitive and psychiatric syndromes. Untreated, symptomatic NS develops in 4% to 9% of 
patients infected with syphilis.126
NS is caused by Treponema pallidum, the spirochete responsible for syphilis. Infection may 
be either symptomatic or asymptomatic. Although NS classically presented with tabes 
dorsalis or general paresis, these are less common today. Instead, patients with NS are 
asymptomatic or may present with seizures, ocular symptoms, or with psychiatric and 
behavioral changes.122 Early NS may occur within 5 years of infection, whereas late NS 
(involving the brain parenchyma) typically occurs within 5 to 25 years of infection. HIV 
infection, however, may accelerate the clinical progression to symptomatic NS.126 The 
general paresis form of NS is the type most commonly associated with psychiatric 
symptoms.122 The psychiatric presentation of NS typically begins insidiously, with mood 
changes including symptoms of mania or depression. Up to 27% of patients with the general 
paresis form of NS develop depression characterized by melancholia, suicidal ideation, and 
psychomotor retardation. Patients also may present with psychosis of acute or insidious 
onset that may mimic schizophrenia.127 Personality changes in patients with NS can include 
emotional lability, antisocial behaviors, anhedonia, social withdrawal, explosive temper, 
giddiness, hypersexuality, or less attention to personal details. As NS progresses, however, 
intellectual functioning worsens. Ultimately, symptoms of dementia predominate, leading to 
disability and, finally, death.122, 127 NS often leads to cortical atrophy and brain lesions. 
Lesions imaged by MRI in the temporoparietal region have been associated with cognitive 
impairments as measured by the Mini Mental-State Examination, whereas lesions in the 
frontal lobes are associated with overall psychiatric morbidity.128 Importantly, although 
prompt treatment of NS is necessary to halt the progression of the illness, it is not expected 
that patients’ mental status will improve completely, because of neuronal loss.122
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Diagnosis of NS is difficult, because unlike other infectious organisms, T pallidum cannot 
be grown in culture (see Table 3). Because so many cases of NS are asymptomatic, many 
infected patients are missed. If the index of suspicion is sufficiently high, however, NS is 
diagnosed serologically by the rapid plasma regain and Venereal Disease Research 
Laboratory tests; CSF may be used in the Venereal Disease Research Laboratory assay. If 
positive, results are confirmed with a microhemagglutination assay for T pallidum or with 
the fluorescent treponemal antibody-absorption assay.122
NS is treated with a 10-day to 14-day course of aqueous penicillin G (18–24 million units 
per day with 3–4 million units given intravenously every 4 hours). An alternative is to treat 
the patient with procaine penicillin (2.4 million units daily intramuscularly) combined with 
probenecid, 500 mg orally, 4 times daily, particularly if compliant with treatment; 
ceftriaxone may be used if the patient is allergic to penicillin.122, 124 Sexual partners of the 
patient also may need evaluation and treatment.112 There has been little documentation 
specifically addressing treatment of psychiatric symptoms associated with NS. There is no 
consensus that antibiotic treatment of neurosyphilis produces a persistent improvement in 
cognition in persons with general paresis.129 A recent study by Sanchez and Zisselman124 
recommended use of a typical antipsychotic, haloperidol, or the atypical agents, quetiapine 
or risperidone, to treat psychosis in patients with NS. An anticonvulsant, such as divalproex 
sodium, also was recommended to address agitation and for mood stabilization.124 Smaller 
case reports supported atypical antipsychotics, such as olanzapine and quetiapine, in 
treatment of NS-associated psychosis.130, 131
CREUTZFELDT-JAKOB DISEASE
Prion disorders have received much attention in the media given recent epidemics of bovine 
spongiform encephalopathy (also known as “mad cow disease”) and the resulting health 
risks associated with possible transmission to humans. There are several diseases caused by 
the prion protein, a novel infectious agent composed of a protein ordinarily found in all 
humans. These diseases are known as “transmissible spongiform encephalopathies” and are 
found in many mammals, including cattle, in the form of bovine spongiform 
encephalopathy, in sheep (known as “scrapie”), and in humans. Prion diseases are believed 
to occur when the naturally occurring form of the prion protein acquires an abnormal 
conformational state that facilitates conversion of surrounding prion protein into the 
pathogenic form, ultimately leading to cell death.132 In the CNS, this process leads to 
marked neurodegeneration causing spongiform changes, and, consequently, a reactive 
astrocytosis.133
Prion disease in humans was first noted in 1920 and 1921 by H G. Creutzfeldt and A.M. 
Jacob, respectively.134 Human prion diseases occur in most of the developed world at a rate 
of 1.0 to 1.5 cases per million per year. In the United States, with a population of 
approximately 330 million, approximately 400 cases of prion disease are diagnosed per year, 
an incidence of 1.2 in 1.0 million. Of human prion diseases, 80% to 95% are sporadic 
Creutzfeldt-Jakob disease (CJD), 10% to 15% are genetic (often familial), and fewer than 
1% are acquired.135 Four forms of CJD exist: (1) sporadic CJD, (2) familial CJD, (3) variant 
CJD, and (4) iatrogenic CJD. Most CJD cases are sporadic in nature, constituting up to 80% 
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to 95% of all reported CJD.135 Sporadic CJD reportedly has a mean survival of 
approximately 6 months (median approximately 5 months), with 85% to 90% of patients 
dying within 1 year. The peak age of onset is 55 to 75 years of age, with median age of onset 
of approximately 67 years and mean of 64 years.136, 137 In sporadic CJD, the misfolding of 
the prion protein occurs likely because of a spontaneous mutation in the gene encoding the 
prion protein. Although the precise significance relating to pathogenesis is unknown, up to 
85% of patients with sporadic CJD are homozygote for 2 copies of the methionine amino 
acid at codon 129 of the prion protein (Met/Met).134
Up to 10% to 15% of CJD cases are familial in origin. Genetic prion diseases historically 
have been divided into 3 forms based on clinicopathologic features: familial CJD, 
Gerstmann-Sträussler-Scheinker syndrome, and fatal familial insomnia. Familial CJD is 
inherited in an autosomal-dominant fashion. Most mutations causing genetic prion disease 
are caused by missense mutations, but several octapeptide repeat insertion mutations and at 
least 5 stop codon mutations exist.138 Among the groups with the highest prevalence of 
familial CJD are Libyan Jews and clusters of families in Chile, Slovakia, Japan, and the 
United States.
Variant CJD (also known as “new-variant CJD”) was first described in 1996 after several 
CJD cases in the United Kingdom were identified as having features that varied from the 
classic presentation of sporadic CJD. It is the only form of human prion disease known to be 
transmitted directly from animals to humans, in most cases through exposure to bovine 
spongiform encephalopathy.139 It occurred because of the practice of feeding sheep 
products, some of which were unfortunately contaminated with the prion disease scrapie, to 
cattle, mostly in the United Kingdom but in other countries as well.139, 140 Food products 
derived from these infected cattle were consumed by humans, a portion of whom developed 
variant CJD. The clinical presentation of variant CJD usually begins with a psychiatric 
prodrome, often at least 6 months before the onset of traditional neurologic symptoms; 
cognitive dysfunction, dysesthesia, cerebellar dysfunction, and involuntary movements (eg, 
dystonia, myoclonus, or chorea) usually appear several months after psychiatric onset. 
Compared with sporadic CJD, the median age of onset of patients with variant CJD is much 
younger than most sporadic cases, approximately 27 years (range 12–74 years), with a 
longer median disease duration of 14.5 months.140 Variant CJD also may be transmissible by 
blood, including transfusions.133, 134
Last, iatrogenic CJD has been documented after exposure to tissues from patients infected 
with CJD or from surgical instruments that have come into contact with those infected. 
Cases have been reported of patients developing CJD after corneal transplantation or dura 
mater grafts from infected donors and by cadaveric pituitary growth hormone.134 Clinically, 
sporadic CJD presents as a rapidly progressive dementia with average disease duration of 
only 1 year until death. Moreover, the neurologic and neuropsychiatric symptoms associated 
with CJD often mimic those found in other dementias, such as Alzheimer disease or Lewy 
body dementia. Common neurologic symptoms may include extrapyramidal signs, 
cerebellar ataxia, sensory complaints, myoclonus, and dysphagia. In advanced stages of 
illness, patients can exhibit akinetic mutism and may ultimately die from aspiration 
pneumonia.132 Although sporadic CJD was classically believed to present with primarily 
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neurologic manifestations with some psychiatric symptoms appearing late in the course of 
illness, more recently it has been demonstrated that psychiatric symptoms commonly occur 
at diagnosis and throughout progression of the disease. A retrospective review of 126 
patients with sporadic CJD at the Mayo Clinic revealed that 80% of the cases demonstrated 
psychiatric symptoms within the first 100 days of illness, with 26% occurring at 
presentation.141 In contrast to sporadic CJD, psychiatric and neuropsychiatric symptoms are 
often the most prominent aspects in the clinical presentation of variant CJD.141
Psychiatric sequelae of CJD include depressed mood and apathy.142 A prodromal phase has 
been described characterized by fatigue, weight loss, impaired sleep, poor judgment, and 
unusual behavior. Patients also may display unusually intense emotional responses; anxiety; 
agitation; and psychotic symptoms, such as delusions and hallucinations.141, 143 At times, 
presentations of primarily depression or psychosis in CJD have made it difficult to 
distinguish from primary psychiatric disorders and led to misdiagnosis or delays in diagnosis 
of CJD.144 Neuropsychologic testing revealed focal cortical deficits in sporadic CJD in 
contrast to more generalized deficits in variant CJD.145
Based on criteria suggested by the World Health Organization, definite diagnosis of sporadic 
CJD involves either neuropathologic examination or detection of the pathogenic scrapie 
form of the prion protein in brain samples by Western blot (see Table 3).146 To receive a 
probable diagnosis of sporadic CJD, patients must have 2 of the following clinical signs: (1) 
cerebellar or visual signs; (2) myoclonus, pyramidal, or extrapyramidal signs; or (3) akinetic 
mutism. Additionally, patients must have detection of the 14-3-3 protein in the CSF or an 
EEG consistent with CJD coupled with disease duration leading to death in less than 2 years, 
or investigation not suggestive of an alternative diagnosis.132
Besides use of clinical symptoms, diagnosis is also based on EEG, imaging, and laboratory 
findings. Typical EEG findings in sporadic CJD include periodic sharp wave complexes that 
have either biphasic or triphasic waves or complexes with mixed spikes. In contrast, EEGs of 
patients with variant CJD do not show periodic sharp wave complexes, but rather have 
nonspecific slow-wave activity.146 MRI has been used extensively in diagnosis of CJD. 
There are abnormalities in the basal ganglia and cortex and a unique pattern of “cortical 
ribboning.” Patients with variant CJD prominently display a pattern of hyperintensity in the 
pulvinar thalami.132 In applying laboratory testing for diagnosis, the detection of the 14-3-3 
protein in the CSF of patients with CJD is both quite sensitive and specific for the sporadic 
form of the disease, although less so in the variant form.147 A clear diagnosis of variant CJD 
also may be made by tonsil biopsy through detection of the scrapie form of the prion 
protein.148
Presently, there is no effective treatment for CJD. A focus of potential treatment strategies 
has been to block accumulation of the pathogenic scrapie form of the prion protein. The 
antimalarial agent quinacrine and the phenothiazines have been tried with little success in 
animal and human trials. Another recent approach has been development of vaccines to 
develop antibodies against the prion protein, although the results of these efforts have been 
unclear thus far.133
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Lyme disease, caused by infection with the tic-borne spirochete Borrelia burgdorferi, has 
been associated with a variety of manifestations, including neuropsychiatric symptoms, or 
neuroborreliosis. Over the past 20 years, there has been significant controversy regarding the 
neuropsychiatric manifestations of neuroborreliosis, which is related to the fact that 
symptoms are often nonspecific (fatigue, sleep disturbance, generalized cognitive 
complaints, low mood, all symptoms of depression); serologic testing may show evidence of 
prior systemic exposure but cannot determine whether or not there is acute disease; and 
symptoms may persist after acute antibiotic treatment. 149, 150 Further, the mechanisms of 
the neuropsychiatric manifestations are not precisely known, being possibly related to direct 
CNS infection with the organism, to acute or long-term inflammatory processes associated 
with systemic or CNS infection, or some combination of these. Over the past 10 years, there 
is accumulating evidence that B burgdorferi may adhere to endothelial cells at the blood-
brain barrier, causing vasculitis and increased blood-brain barrier permeability, leading to 
CNS invasion and adherence to astrocytes, resulting in a deleterious inflammatory 
cascade.151 The resulting changes in the CNS, including abnormalities in subcortical 
frontotemporal white matter and basal ganglia functioning,152 may explain the more chronic 
neuropsychiatric symptoms and why antibiotic treatment of these chronic symptoms is 
generally not associated with improvement in symptoms or CNS pathology.149–151
In the early stages of acute Lyme disease, patients may present with meningitis, cranial 
neuritis, and radiculoneuritis.150 In many such cases, there are positive CSF findings for B 
burgdorferi antibody (immunoglobulin G) and elevated protein. Cognitive deficits associated 
with acute and chronic Lyme disease include poor attention and concentration, impaired 
verbal memory, word-finding difficulties, psychomotor slowing, and executive dysfunction, 
all consistent with subcortical-frontal pathology. Interestingly, study of patients with Lyme 
disease with chronic cognitive complaints indicates that those with abnormal CSF are more 
likely than those with normal CSF to have actual neuropsychologic deficits. In those with 
normal CSF, cognitive complaints are more likely to be associated with concurrent 
depression.150 Psychiatrically, patients with both acute and chronic symptoms of 
neuroborreliosis may present with depression, mood lability, irritability, anxiety, panic 
attacks, and more rarely, mania, psychosis, and obsessive-compulsive symptoms.152 There 
are no large-scale well-controlled studies, however, to suggest that patients with Lyme 
disease have a greater burden of such symptoms than the general population.
In terms of diagnosis, neurologic examination is usually nonfocal. Bedside cognitive 
evaluation may be normal to mildly abnormal and more extensive neuropsychologic testing 
may be necessary to detect the characteristic deficits mentioned previously. Lumbar 
puncture and CSF evaluation may reveal B burgdorferi DNA detected by polymerase chain 
reaction and antibody to B burgdorferi, nonspecific protein elevation, and CSF pleocytosis. 
The CSF may be normal, however, in a substantial number of cases. Standard structural 
neuroimaging, including brain CT or MRI with contrast, is often normal in both the acute 
and chronic stages of the disease. Quantitative single-photon emission CT of the brain has 
proved more useful in detecting abnormality, including hypoperfusion in frontal subcortical 
and cortical regions.153 This method has been used to follow response to antibiotic 
treatment.
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In terms of treatment, intravenous infusion of ceftriaxone, 2 g daily for 30 days, followed by 
oral doxycycline, 200 mg daily for 60 days, has been tested.149 Other regimens in the 
literature include intravenous penicillin or a derivative, amoxicillin. Although such regimens 
have been helpful for neuroborreliosis with clear evidence of abnormal CSF in acute and 
chronic disease, results have been less favorable in patients with chronic symptoms and 
minimal objective evidence of CNS infection.
In terms of psychotropic medication treatment for psychiatric comorbidities, the literature is 
quite sparse. Treatment is generally symptomatic, addressing symptoms of depression (ie, 
with selective serotonin reuptake inhibitors), fatigue and cognitive complaints (ie, with 
psychostimulants or modafinil), and mood lability and psychosis (ie, with atypical 
neuroleptics). Given the subcortical involvement of the spirochete, however, it is important 
to assess for extrapyramidal side effects with the use of atypical neuroleptic medications.
SUMMARY
This article reviews the clinical characteristics and treatment of a number of infectious 
diseases that have prominent neuropsychiatric manifestations. Although each entity has 
unique characteristics, there are several common themes that are important for clinicians to 
remember. First, maintain an index of suspicion, especially when patients present with new-
onset psychiatric symptoms without a history of prior psychiatric illness. It is commonplace 
to overlook medical or neurologic illness in assuming a primary psychiatric diagnosis, 
including sexual risk behavior, blood-borne exposures, and travel history. Third, although a 
thorough diagnostic workup is necessary to identify and treat the infection, equally 
important is a full characterization of the psychiatric and cognitive symptoms associated 
with the infection so as to track the effects of treatment. This becomes particularly important 
when patients have residual deficits that affect everyday function and ability to work. 
Finally, it is important to remember that concurrent treatment with antibiotics and 
psychotropic medications is often necessary. For most of these infectious diseases, formal 
study of psychotropic medications is relatively infrequent, so clinicians should be vigilant 
regarding potential drug-drug and drug-disease interactions. Fortunately, when these 
principles are followed, neuropsychiatric manifestations of infectious diseases can be 
successfully identified and treated.
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Box 1 Differential diagnosis of psychiatric disorders and symptoms in 
medical inpatients with HIVAIDS
• Primary psychiatric disorder
• CNS HIV infection (minor neurocognitive disorder and HIV-associated 
dementia)
• CNS opportunistic illnesses and cancers (see Table 2)
• Substance intoxication and withdrawal
• Neuropsychiatric complications of hepatitis C and its treatments
• Neuropsychiatric side effects of HIV medications
• Drug-drug interactions
• Endocrine abnormalities (eg, hypogonadism, adrenal insufficiency, thyroid 
disease)
Abbreviations: CNS, central nervous system; HIV, human immunodeficiency virus.
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Box 2 Diagnostic evaluation of the medical inpatient with HIV-AIDS and 
neuropsychiatric disturbances
• Medical evaluation with screening laboratories: complete blood count, 
chemistry screen (including liver and renal function tests), urinalysis, chest 
radiograph, electrocardiogram, blood and urine cultures (when applicable)
• Psychiatric diagnostic interview including personal and family history
• Cognitive screen (HIV Dementia Scale)
• Additional laboratories when applicable: illicit drug toxicology screen, serum 
psychotropic drug levels, thyroid function tests, antithyroid antibodies, 
vitamin B12 and B6 levels, total or bioavailable testosterone, 
dehydroepiandrosterone sulfate, adrenocorticotropic stimulation test, 24-hour 
urine cortisol
• Evaluation for hepatitis C (including viral load)
• Review of antiretroviral regimen for neuropsychiatric side effects
• Review of psychotropic mediations for efficacy, neuropsychiatric side effects, 
drug interactions
• Neuroimaging (MRI, magnetic resonance spectroscopy)
• Lumbar puncture
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KEY POINTS
• Among the critically ill, infectious diseases can play a significant role in the 
etiology of neuropsychiatric disturbances.
• All critical care physicians are familiar with delirium as a secondary 
complication of systemic infection.
• This article focuses on key infectious diseases that commonly and directly 
produce neuropsychiatric symptoms, including direct infection of the central 
nervous system, human immunodeficiency virus infection, and AIDS.
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